A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

← catalyst calendar

NCT06337032 · readout ≤ 2,781 d

Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.

Phase

Phase 4

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

350estimated

Sites

Countries

Argentina, Panama, South Africa +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-08-27

actual

When the study began enrolling

Primary completion

Mar 2034

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2034

estimated

The whole study's end, after follow-up

First posted

2024-03-29

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-10

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

HIV-1-infection

Interventions

Drug: F/TAF (High Dose Tablet) — also filed as Descovy®
Drug: F/TAF (Low Dose Tablet)
Drug: F/TAF (Lowest Dose Tablet)
Drug: F/TAF (High Dose TOS)
Drug: F/TAF (Low Dose TOS)
Drug: F/TAF (Lowest Dose TOS)
Drug: E/C/F/TAF — also filed as Genvoya®
Drug: E/C/F/TAF (Low Dose)
Drug: Cobicistat (High Dose) — also filed as GS-9350, Tybost®
Drug: Cobicistat (Low Dose) — also filed as GS-9350
Drug: Cobicistat (TOS) — also filed as GS-9350
Drug: B/F/TAF (High Dose) — also filed as Biktarvy®, GS-9883/F/TAF
Drug: B/F/TAF (Low Dose) — also filed as GS-9883/F/TAF
Drug: B/F/TAF (High Dose TOS) — also filed as GS-9883/F/TAF
Drug: B/F/TAF (Low Dose TOS) — also filed as GS-9883/F/TAF
Drug: B/F/TAF (Lowest Dose TOS) — also filed as GS-9883/F/TAF
Drug: 3rd ARV Agent
Drug: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
Drug: ATV
Drug: DRV
Drug: Lopinavir Boosted with ritonavir (LPV/r)

Primary outcome

what the primary-completion date above is the date OF

Number of Eligible Participants Who Have Received Access to the Study Drug(s) in the Study

measured Up to 9.5 Years

Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed